Organoids are three-dimensional (3D) constructs that can be developed from embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), somatic SCs, and cancer cells in specific 3D culture system. Organoids have three basic characteristics: first, they contain multiple cell types of the in vivo counterparts; second, the cells organize similarly to the primary tissues; third, they function specifically to the parent organs. These characteristics make organoids an extremely exciting and promising technology that holds a promising future for therapeutics. Their reliability, robustness, and amenability for research have yielded enormous downstream applications, highlighting their role in recapitulating homeostasis and diseases.
Organoid technology bridges the gap between conventional two-dimensional cell line culture and in vivo models. The near-physiological technology can virtually recapitulate organ development and human diseases, such as infectious diseases, cancer, and genetic abnormality. Organoids can more accurately predict drug responses, and can serve as an excellent platform for drug development, including efficacy evaluation, toxicity testing and pharmacokinetics analysis. In addition, organoids can also be used to explore the possible optimized treatment strategies for each individual patient. Furthermore, organoid technology is a promising strategy for regeneration medicine and transplantation, which can overcome the deficiency in the supply of healthy donor tissues and inherent immunological rejection by establishing isogenic organoids from patient biopsies. In short, organoids hold huge potential for clinical applications and make basic research closer to clinical practice.
At OrganoLab, our vision is to use innovative stem cells and organoid techniques to change the outcome of clinical practice. Please contact us to use our organoid and organ-on-a-chip technology to generate standardized and reproducible data.
Online Inquiry